Results from a study using cutting-edge genome editing for hard-to-treat blood disorders were presented at the 62nd American Society of Hematology (ASH) Annual, Meeting and Exposition held virtually from December 5 – 8, 2020.

In the study, researchers used CRISPR/Cas9 to treat beta-thalassemia and sickle cell disease. In this study, researchers used a new, revolutionary approach for the treatment of patients diagnosed with these inherited blood disorders. The results of the study, presented by Haydar Frangoul, M.D., The Children’s Hospital at TriStar Centennial and Sarah Cannon Research Institute, demonstrated remarkable improvements in all ten participating patients.[1][2]

The researchers reported promising interim safety and efficacy data from 10 patients who received an investigational gene-editing based therapy, CTX001, the first to test a CRISPR-Cas9 gene-editing therapy in humans for a genetic disease.

Sickle cell disease affects approximately 100,000 people in the United States. And globally, approximately 400,000 infants are born each year with sickle cell disease. [3][4]

Recognized for its abnormally shaped red cells, sickle cell disease can cause a variety of health problems, including hemolytic anemia, episodes of severe pain, called vaso-occlusive crises, as well as progressive and irreversible organ damage, and strokes, leading to a decreased health-related quality of life (hrQoL), and early death.[5]

Advertisement #3

Standard of care
Today, the standard curative treatment for sickle cell disease is allogeneic hematopoietic stem-cell transplantation. If matched with a sibling donor, transplantation is known to be curative in more than 90% of patients. This approach is approach has limitations including a higher risk of complications in older patients, a risk of severe graft-versus-host disease (GVHD), and lack of an available matched sibling in approximately 80% of cases.[6][7]

Patients with transfusion-dependent thalassemia are dependent on blood transfusions from early childhood. The only available cure for both diseases is a bone marrow transplant from a closely related donor, an option that is not available for the vast majority of patients because of difficulty locating matched donors, the cost, and the risk of complications.

In the studies, the researchers’ goal is to functionally cure the blood disorders using CRISPR/Cas9 gene-editing by increasing the production of fetal hemoglobin, which produces normal, healthy red blood cells as opposed to the misshapen cells produced by faulty hemoglobin in the bodies of individuals with the disorders.

The clinical trials involve collecting stem cells from patients. Researchers edit the stem cells using CRISPR-Cas9 and infuse the gene-modified cells into the patients. Patients remain in the hospital for approximately one month following the infusion.

Prior to receiving their modified cells, the seven patients with beta-thalassemia required blood transfusions approximately every three to four weeks and the three patients with sickle cell disease suffered episodes of severe pain roughly every other month. All the individuals with beta-thalassemia have been transfusion independent since receiving the treatment, with three to 18 months of follow-up after CTX001 infusion. Similarly, none of the individuals with sickle cell disease have experienced vaso-occlusive crises since CTX001 infusion. All patients showed a substantial and sustained increase in the production of fetal hemoglobin.

Saftey
Researchers report that the safety of CTX001 infusion was generally consistent with the chemotherapy regimen received prior to cell infusion. Four serious adverse events related or possibly related to CTX001 were reported in one patient with thalassemia: headache, haemophagocytic lymphohistiocytosis (HLH), acute respiratory distress syndrome, and idiopathic pneumonia syndrome.

The patients have now recovered.

Unmet medical need
“There is a great need to find new therapies for beta-thalassemia and sickle cell disease,” said Haydar Frangoul, MD, Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcare’s TriStar Centennial Medical Center.

“What we have been able to do through this study is a tremendous achievement. By gene editing the patient’s own stem cells, we may have the potential to make this therapy an option for many patients facing these blood diseases,” Frangoul concluded.

Because of the precise way CRISPR-Cas9 gene editing works, Frangoul suggested the technique could potentially cure or ameliorate a variety of diseases that have genetic origins.

“Given that the only Food and Drug Administration (FDA) -approved cure for sickle cell disease, a bone marrow transplant, is not widely accessible, having another curative option would be life-changing for a large number of the sickle cell disease population,” noted Catherine Bollard, MD, of Children’s National Research Institute and George Washington University.

“While longer follow-up data are needed, this study is extremely exciting for the field,” she added.

The trial was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals.

Abstract
[1] Frangoul H, Bobruff Y, Cappellini MD, Corbacioglu S, Fernandez CM, De la Fuente J, Grupp SA, Handgretinger R, et al, Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β- Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9–Modified CD34+ Hematopoietic Stem and Progenitor Cells (Abstract #4)

Reference
[2] Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, De la Fuente J, Grupp S, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaH. N Engl J Med. 2020 Dec 5; DOI: 10.1056/NEJMoa2031054
[3] Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010;24:199-214.2.
[4] Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381: 142-51
[5] Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2020 Dec 5; DOI: 10.1056/NEJMoa2029392
[6] Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 2017; 129: 1548-56.4.
[7] Bernaudin F, Dalle J-H, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica 2020; 105: 91-101.

Featured image: The ASH Store at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesy © 2019. ASH/Scott Morgan. Used with permission.

Advertisement #5